Harmonization of the intracellular cytokine staining assay
Harmonization of the intracellular cytokine staining assay
Active immunotherapy for cancer is an accepted treatment modality aiming to reinforce the T-cell response to cancer. T-cell reactivity is measured by various assays and used to guide the clinical development of immunotherapeutics. However, data obtained across different institutions may vary substantially making comparative conclusions difficult. The Cancer Immunotherapy Immunoguiding Program organizes proficiency panels to identify key parameters influencing the outcome of commonly used T-cell assays followed by harmonization. Our successes with IFN?-ELISPOT and peptide HLA multimer analysis have led to the current study on intracellular cytokine staining (ICS). We report the results of three successive panels evaluating this assay. At the beginning, 3 out of 9 participants (33 %) were able to detect >6 out of 8 known virus-specific T-cell responses in peripheral blood of healthy individuals. This increased to 50 % of the laboratories in the second phase. The reported percentages of cytokine-producing T cells by the different laboratories were highly variable with coefficients of variation well over 60 %. Variability could partially be explained by protocol-related differences in background cytokine production leading to sub-optimal signal-to-noise ratios. The large number of protocol variables prohibited identification of prime guidelines to harmonize the assays. In addition, the gating strategy used to identify reactive T cells had a major impact on assay outcome. Subsequent harmonization of the gating strategy considerably reduced the variability within the group of participants. In conclusion, we propose that first basic guidelines should be applied for gating in ICS experiments before harmonizing assay protocol variables.
967-978
Welters, Marij J.P.
ece995e7-8d4c-431d-83a9-fc0a24f6fdf4
Gouttefangeas, Cécile
e06644af-a88f-4d60-b11c-debfaffefd0d
Ramwadhdoebe, Tamara H.
da9361db-4d0c-440f-9c30-a72be7aa972a
Letsch, Anne
6ec5772a-5a2c-4978-8deb-f544a748b84c
Ottensmeier, Christian H.
42b8a398-baac-4843-a3d6-056225675797
Britten, Cedrik M.
a303deac-ffba-4a55-9a7e-fa5e158c0f8d
van der Burg, Sjoerd H.
1e880617-4966-4046-b70c-0ef451c2c2ab
July 2012
Welters, Marij J.P.
ece995e7-8d4c-431d-83a9-fc0a24f6fdf4
Gouttefangeas, Cécile
e06644af-a88f-4d60-b11c-debfaffefd0d
Ramwadhdoebe, Tamara H.
da9361db-4d0c-440f-9c30-a72be7aa972a
Letsch, Anne
6ec5772a-5a2c-4978-8deb-f544a748b84c
Ottensmeier, Christian H.
42b8a398-baac-4843-a3d6-056225675797
Britten, Cedrik M.
a303deac-ffba-4a55-9a7e-fa5e158c0f8d
van der Burg, Sjoerd H.
1e880617-4966-4046-b70c-0ef451c2c2ab
Welters, Marij J.P., Gouttefangeas, Cécile, Ramwadhdoebe, Tamara H., Letsch, Anne, Ottensmeier, Christian H., Britten, Cedrik M. and van der Burg, Sjoerd H.
(2012)
Harmonization of the intracellular cytokine staining assay.
Cancer Immunology Immunotherapy, 61 (7), .
(doi:10.1007/s00262-012-1282-9).
(PMID:22714399)
Abstract
Active immunotherapy for cancer is an accepted treatment modality aiming to reinforce the T-cell response to cancer. T-cell reactivity is measured by various assays and used to guide the clinical development of immunotherapeutics. However, data obtained across different institutions may vary substantially making comparative conclusions difficult. The Cancer Immunotherapy Immunoguiding Program organizes proficiency panels to identify key parameters influencing the outcome of commonly used T-cell assays followed by harmonization. Our successes with IFN?-ELISPOT and peptide HLA multimer analysis have led to the current study on intracellular cytokine staining (ICS). We report the results of three successive panels evaluating this assay. At the beginning, 3 out of 9 participants (33 %) were able to detect >6 out of 8 known virus-specific T-cell responses in peripheral blood of healthy individuals. This increased to 50 % of the laboratories in the second phase. The reported percentages of cytokine-producing T cells by the different laboratories were highly variable with coefficients of variation well over 60 %. Variability could partially be explained by protocol-related differences in background cytokine production leading to sub-optimal signal-to-noise ratios. The large number of protocol variables prohibited identification of prime guidelines to harmonize the assays. In addition, the gating strategy used to identify reactive T cells had a major impact on assay outcome. Subsequent harmonization of the gating strategy considerably reduced the variability within the group of participants. In conclusion, we propose that first basic guidelines should be applied for gating in ICS experiments before harmonizing assay protocol variables.
This record has no associated files available for download.
More information
Accepted/In Press date: 2 May 2012
Published date: July 2012
Organisations:
Cancer Sciences
Identifiers
Local EPrints ID: 396351
URI: http://eprints.soton.ac.uk/id/eprint/396351
ISSN: 0340-7004
PURE UUID: 5a493d10-03fe-4c11-9960-c2cf88e7c88f
Catalogue record
Date deposited: 08 Jun 2016 15:31
Last modified: 15 Mar 2024 00:52
Export record
Altmetrics
Contributors
Author:
Marij J.P. Welters
Author:
Cécile Gouttefangeas
Author:
Tamara H. Ramwadhdoebe
Author:
Anne Letsch
Author:
Cedrik M. Britten
Author:
Sjoerd H. van der Burg
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics